Elsevier

The Lancet

Volume 324, Issue 8405, 29 September 1984, Pages 707-711
The Lancet

ACYCLOVIR VERSUS VIDARABINE IN HERPES SIMPLEX ENCEPHALITIS: Randomised Multicentre Study in Consecutive Swedish Patients

https://doi.org/10.1016/S0140-6736(84)92623-0Get rights and content

Abstract

127 patients with suspected herpes simplex encephalitis (HSE) were entered in a prospective randomised study of acyclovir 10 mg/kg 8-hourly versus vidarabine 15 mg/kg daily for 10 days. The patients were consecutive and nearly all Swedish cases of HSE were included; they were treated in six university infectious diseases departments. The diagnosis of HSE was verified by brain biopsy and/or antibody responses in serum and cerebrospinal fluid. Of 53 confirmed cases of HSE (corresponding to 2·3 cases per million inhabitants per year in Sweden), 51 (27 acyclovir, 24 vidarabine) were evaluable for analysis of efficacy. The mortality was 19% in the acyclovir-treated group versus 50% in the vidarabine group (p=0·04). At 6 months of observation 15 (56%) of 27 acyclovir-treated patients had returned to normal life compared with 3 (13%) of 24 vidarabine-treated patients (p = 0·002); and the numbers who died or had severe sequelae were 9 (33%) and 19 (76%), respectively (p=0·005). No important or new adverse events were recognised.

References (25)

  • S. Jeansson et al.

    Evaluation of solubilized herpes simplex virus membrane antigen in ELISA

    J Clin Microbiol

    (1983)
  • G. Tibbling et al.

    Principles of albumine and IgG analyses in neurological disorders. I. Establishment of reference values

    Scand J Clin Lab Invest

    (1977)
  • Cited by (478)

    • Acyclovir dosing in herpes encephalitis: A scoping review

      2024, Journal of the American Pharmacists Association
    • Contribution of diffusion-weighted imaging to distinguish herpetic encephalitis from auto-immune encephalitis at an early stage

      2023, Journal of Neuroradiology
      Citation Excerpt :

      Autoimmune (AI) encephalitides and infectious encephalitides including herpes simplex virus (HSV) are the most common causes and require different treatments.4 Intravenous aciclovir has been shown to reduce mortality by approximately 70% to 10–20% in HSV encephalitis,5 and immunomodulatory therapy improves outcome in patients with AI encephalitis.6,7 In clinical practice, the early distinction of HSV and AI encephalitides can be challenging.

    • Viral encephalitis

      2023, Molecular Medical Microbiology, Third Edition
    • Acyclovir-Induced Nephrotoxicity in Adults with Viral Encephalitis

      2024, Journal of the College of Physicians and Surgeons Pakistan
    • Outcome and Sequelae of Infectious Encephalitis

      2024, Journal of Clinical Neurology (Korea)
    View all citing articles on Scopus
    View full text